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Abstract
Background: Interleukin (IL)-27 is a cytokine belonging to the IL-6/IL-12 cytokine family that is secreted by
activated macrophages and dendritic cells and which strongly acts on T-cells and cells of the innate immune
system. Not much is known about possible effects of IL-27 on other cell types. It signals via the common IL-6-type-
cytokine receptor chain gp130 and the IL-27-specific chain WSX-1. We previously described that IL-27 also
stimulates hepatoma cells and primary hepatocytes. The aim of this study was to investigate whether IL-27 would
also act on hepatic stellate cells (HSC), the second most abundant hepatic cell type, which would demonstrate a
more general role of this cytokine in the liver.
Results: Using a human HSC line and primary rat HSC we investigated the signalling characteristics of IL-27 in
these cells. We show that IL-27 activates signal transducer and activator of transcription (STAT) 1 and to a minor
extent STAT3 in a human HSC cell line and that it leads to the induction of STAT1 target genes such as interferon
response factor-1, myxovirus resistance A and STAT1 itself. Similarly we find that IL-27 also elicits STAT1-dependent
responses in primary rat HSC.
Conclusions: We provide the first evidence for a function of IL-27 in HSC and show that its responses resemble
Interferon-g-like functions in these cells. Our data suggests that IL-27 may play an important role in the context of
liver inflammation by acting on the different liver cell types.
Background
Liver inflammation is most often induced by viral infec-
tions, alcohol, drugs or chemical intoxication. Generally,
it is associated with liver fibrosis, a wound-healing
response to liver injury [1]. Among the hepatic cell
types, hepatic stellate cells (HSC) are most important
for this process. Activated HSC migrate and proliferate
at the site of injury and perpetuate the inflammation. A
key factor for the transformation of quiescent HSC into
fibrogenic myofibroblasts is the cytokine transforming
growth factor-b (TGF-b) [2].
Interleukin-27 (IL-27) is a type-I-cytokine belonging to
the IL-6/IL-12 superfamily of cytokines [3]. It is predo-
minantly secreted by activated macrophages and dendri-
tic cells. As the other IL-12 family members, IL-12 and
IL-23, IL-27 has profound effects on T-cells and acts on
innate immune cells [4,5]. Most studies investigated the
effects of IL-27 on CD4+ T-cells but not much is
known about possible effects of IL-27 on other cell
types. IL-27 signals via a receptor complex composed of
the IL-27-specific receptor chain WSX-1 [3] and the
common receptor subunit of IL-6-type cytokines, gp130
[6]. It is thus also a member of the IL-6-type cytokine
family. We previously reported a function of IL-27 in
hepatoma cells and primary hepatocytes and showed
that IL-27 responses are not restricted to the classical
immune cells. IL-27 was shown to exert Interferon-g-
like functions in hepatocytes/hepatoma cells and to con-
tribute to the antiviral response in these cells [7]. The
potential importance of this finding is highlighted by a
recent study showing that Hepatitis B virus (HBV)
enhances IL-27 expression in vivo and in vitro [8].
In the present study, we describe for the first time that
IL-27 acts on hepatic stellate cells and elicits an efficient
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1 response in these cells.
Results
IL-27 induces STAT1 and STAT3 phosphorylation in a
human hepatic stellate cell line
Using the human LX-2 cell line, we first assessed
whether these cells express both IL-27 receptor chains.
This cell line retains key features of primary HSC and
the gene expression profile shows strong similarities to
those of primary cells (98.7%) [9]. As shown in the
FACS-analysis in figure 1, we observed that both IL-27
receptor chains, gp130 and WSX-1, are expressed on
these cells. Next, the cells were treated with IL-27 for
up to 12 hours and tyrosine phosphorylation of
STAT3 (pY705) and STAT1 (pY701) was assessed by
Western blot analysis. As a control, the cells were sti-
mulated with IFNg or with Interleukin-6 (IL-6)
together with its soluble receptor, sIL-a.I L - 2 7i n d u c e s
a sustained phosphorylation of STAT1 and STAT3
(figure 2A). As expected, IFNg induced mainly STAT1
phosphorylation whereas IL-6 initiated a rapid and
pronounced STAT3 phosphorylation. The kinetics of
STAT1 and STAT3 activation by IL-27 were compar-
able but peaked at later time points if compared to the
phosphorylation kinetics obtained after IL-6 stimula-
tion. As previously observed IL-6 leads to a weak and
transient phosphorylation of STAT1 (10, 20 and 30
min time points in figure 2A) [10]. This underlines
that STAT1 phosphorylation itself is not a good indi-
cator for the formation of active STAT1 homodimers,
especially if only early time points are considered. For
example, upon treatment of hepatoma cells and pri-
mary human macrophages with IL-6-type cytokines
(e.g. IL-6 or OncostatinM) STAT1 phosphorylation
can be observed but most of the phosphorylated
STAT1 is rather trapped in STAT1/STAT3 heterodi-
meric complexes [10]. We thus performed electro-
phoretic mobility shift assays (EMSA) to examine
whether phosphorylated STAT1 is forming homodi-
mers upon treatment of LX-2 cells with IL-27 (figure
2B). As controls we used cells stimulated with IL-6/
sIL-a or IFNg. The sustained formation of STAT1/
STAT1 complexes shows that IL-27 induces a persis-
tent STAT1 activation in these cells.
IL-27 mediates STAT1-dependent responses in human
hepatic stellate cells
As IL-27 only led to a weak STAT3 phosphorylation
and DNA-binding (figure 2), we monitored the induc-
tion of the STAT3-dependent feedback regulator sup-
pressor of cytokine signalling (SOCS)-3 upon
stimulation of LX-2 cells with IL-27 for up to 1 h. Fig-
ure 3A demonstrates that SOCS3 mRNA was hardly
upregulated by IL-27 whereas the IL-6 control promi-
nently induced SOCS3 expression. Longer treatments of
the cells (up to 24 h) with IL-27 did also not further
increase SOCS3 mRNA levels (data not shown).
To assess whether IL-27 induces an efficient STAT1
response, we investigated whether IL-27 would regulate
STAT1-dependent gene transcription and thereby med-
iate interferon-like responses. We performed Western
blot analyses in LX-2 cells to monitor STAT1-depen-
dent protein expression upon treatment of these cells
with IL-27 or IFNg. Figure 3B shows that IL-27 upregu-
lates the STAT1-dependent genes STAT1, interferon
response factor-1 (IRF-1) as well as myxovirus resistance
A (MxA), which is implicated in the antiviral response
after IFN-treatment of cells [11]. Although protein upre-
gulation of these genes was stronger upon treatment
with IFNg, it can be concluded that IL-27 leads to IFN-
like responses in these cells.
Figure 1 LX-2 cells express the IL-27 receptor chains gp130 and WSX-1. For FACS-analysis, LX-2 were incubated with a monoclonal
antibody against human gp130 or human WSX-1 followed by a secondary PE-conjugated antibody. The grey histograms represent cells treated
with secondary antibody only and the open histograms represent gp130 or WSX-1 surface staining.
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In order to test whether IL-27 also acts on HSC in pri-
mary culture we isolated rat HSC and stimulated them
with IL-27 or IFNg for different times. As illustrated in
figure 4A, treatment of these cells with IL-27 or IFNg
leads to a sustained phosphorylation of STAT1. In com-
parison, IL-27 only leads to a weak increase in STAT3-
phosphorylation after 1 hour. Furthermore, as already
observed in the HSC line (i.e. LX-2), IL-27 upregulates
the STAT1-dependent proteins STAT1 and MxA in pri-
mary HSC and thereby induces a response resembling
that of IFNg (figure 4B).
IL-27 stimulation does not affect the expression of Smad2
and Smad3 or the activation of a Smad-dependent
reporter construct
It was recently reported that the TGF-a/Smad3 pathway
is accelerated in STAT1-deficient mice [12]. In addition,
Weng et al. reported that prestimulation of rat HSC
with IFNg for 6 h or 12 h impairs the intrinsic phos-
phorylation of Smad2 and Smad3 that occurs by
autocrine TGF-b stimulation [13]. Furthermore, they
found Smad2 and Smad3 expression to be reduced to a
comparable degree in these conditions. The effects on
Smad2 were most prominent after a pretreatment of 6 h
whereas Smad3 was most affected after a 12 h prestimu-
lation [13]. We performed similar experiments to inves-
tigate whether stimulation of LX-2 cells or rat HSC with
either IFNg or IL-27 would affect Smad2 and Smad3
expression. As shown in figure 5A and 5B, we did not
observe reduced expression of either Smad2 or Smad3
although STAT1 was clearly activated. Similarly we did
not detect a clear reduction of the intrinsic Smad3
phosphorylation (figure 5B). We repeated the experi-
ment and additionally treated the cells with TGF-b fol-
lowing pretreatment with IL-27 or IFNg (figure 5C and
5D). Similarly, we did not detect a reduction of Smad2
or Smad3 expression levels. TGF-b stimulation slightly
increased Smad3 phosphorylation (figure 5D) but presti-
mulation with either IL-27 or IFNg did not impair this
activation. A reduction in Smad3 phosphorylation was
always paralleled by a reduction in the loading control
(tubulin detection). To further substantiate this finding,
Figure 2 IL-27 treatment induces STAT1 and STAT3 phosphorylation in human hepatic stellate cells. A: LX-2 cells were stimulated with
each 30 ng/mL IL-27, IFNg and IL-6 together with sIL-a (500 ng/mL) for the indicated times. After lysis, cellular proteins were resolved by SDS-
PAGE and tyrosine phosphorylation of STAT1 and STAT3 was detected by Western blot analysis using phospho-specific antibodies for pY701-
STAT1 and pY705-STAT3. STAT protein expression was monitored by stripping and re-probing the blot with antibodies directed against total
STAT1 and STAT3. Equal loading of the samples was assessed by probing the blot with an antibody against tubulin. B: LX-2 cells were
stimulated with 30 ng/mL IL-27, IL-6 or IFNg for the times indicated and nuclear extracts were prepared. These were analyzed by EMSA and
STAT3/3, STAT3/1 and STAT1/1 dimer species were visualized by autoradiography.
Schoenherr et al. Cell Communication and Signaling 2010, 8:19
http://www.biosignaling.com/content/8/1/19
Page 3 of 10we performed a reporter gene analysis using a CAGA-
reporter construct that binds the Smad2/Smad3/Smad4
complex after phosphorylation of Smad2 and Smad3.
The cells were stimulated with TGF-b1o rI L - 2 7a l o n e
or in combination with both cytokines. We observed an
increase in luciferase activity upon treatment of the cells
with TGF-b1 for 2 or 16 hrs but this induction was not
inhibited by IL-27 co-stimulation (figure 5E). Taken
together, we could not confirm inhibitory effects of
IFNg prestimulation on Smad2 and Smad3 expression
or Smad3 phosphorylation. Similarly, pretreatment with
IL-27 did not affect these parameters.
Discussion
Interleukin-27 was previously described to be involved
in inflammatory processes within the gastrointestinal
tract. It was shown to play a key role in the context of
Con-A-induced hepatitis [14], Crohn’s Disease [15] as
well as in the initiation and progression of colon carci-
noma [16,17]. Furthermore, IL-27 was recently reported
Figure 3 IL-27 mediates a STAT1 response in human LX-2 cells. A: Real-time PCR analysis of total cellular mRNA monitoring the expression
of the STAT3-dependent gene SOCS3 in LX-2 cells after stimulation with IL-27 (30 ng/mL) for the times indicated. As a control, the cells were
stimulated with IL-6/sIL6R (30 ng/mL/500 ng/mL) for 60 min. Beta-actin was used as internal reference to normalize the target transcripts.
Standard deviations of a triplicate experiment are given. B: Western blot analysis monitoring upregulation of the STAT1-dependent STAT1, IRF-1
and MxA protein expression upon stimulation of LX-2 cells with 30 ng/mL IL-27 or IFNg for up to 24 h. Expression levels of PLCg are provided to
compare the protein amount in the samples.
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of hepatocellular carcinoma [18]. These studies highlight
the importance of IL-27 expression in the gastrointest-
inal tract and the liver. However, the reported functions
of IL-27 were all restricted to infiltrating immune cells
such as T-cells and natural killer cells. Recently, we
reported a first function for IL-27 on a hepatic cell type,
namely hepatocytes [7]. Here we investigated whether
the second most abundant liver cell type (i.e. HSC) also
responds to IL-27. We show that IL-27 induces a
STAT1 response in these cells and upregulates proteins
involved in antiviral responses.
The members of the IL-6 type family of cytokines play
important roles in the liver as they contribute to the
acute-phase response of the liver as well as liver regen-
eration [19-21]. These functions of IL-6-type cytokines
are largely dependent on the activation of the transcrip-
tion factor STAT3 and the formation of activated
STAT3/STAT3 dimers. The activation of STAT3 is
mediated via the IL-6-type cytokine receptor chains
gp130, oncostatinM receptor and leukemia inhibitory
factor receptor [6]. Although these receptors can also
recruit STAT1 and lead to its phosphorylation, IL-6-
type cytokines such as IL-6 and OSM fail to induce an
efficient STAT1 response in cell types such as hepato-
cytes and macrophages [10,22,23]. It was reported that
the majority of the phosphorylated STAT1 is trapped in
STAT1/STAT3 heterodimers [10]. This provides an
explanation for the fact that IL-6 and OSM induce an
interferon-like response in STAT3 knock-out cells
[22,23]. In this case, the lack of STAT3 prevents the for-
mation of heterodimers and will thereby lead to the for-
mation of STAT1 homodimers.
IL-27 signals via a signalling complex containing the
STAT3 activating receptor chain gp130 and a STAT1
activating receptor chain WSX-1 [24]. Here we report
that IL-27 mediates an efficient STAT1 response in
HSC (figures 3B and 4). Furthermore, we only found a
weak induction of a STAT3-dependent gene, SOCS3
(figure 3A). In classical immune cells such as CD4+ T
cells and macrophages, the importance of STAT1 for
the various biological activities of IL-27 was shown
[25-27]. However, it was also reported that IL-27 acti-
vates both STAT1 and STAT3 in early activated T-cells
whereas it displays a preferential activation of STAT3 in
fully activated CD4+ T cells [28]. This suggests that spe-
cific IL-27 responses may be the result of differently
regulated STAT1 and STAT3 responses and that the
extent of STAT3 activation (via gp130) and STAT1 acti-
vation (via WSX-1) may depend on the cell type and/or
on the activation status of the cell. Such a preference
Figure 4 IL-27 stimulation leads to STAT1 phosphorylation and
induces STAT1-dependent protein expression in primary
hepatic stellate cells. A: Primary rat HSC were isolated as
described in the Materials and Methods section and were treated
with murine IL-27 (30 ng/mL) or with murine IFNg (30 ng/mL) at
day 5 after isolation for the times indicated. Phosphorylation of
STAT1 and STAT3 was monitored by Western blot analysis as
described for Figure 2. B: Western blot analysis monitoring
upregulation of STAT1 and MxA protein expression upon
stimulation of primary rat HSC with 30 ng/mL IL-27 or IFNg for up
to 24 h. Expression levels of PLCg are provided to compare protein
loading in the individual samples.
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Page 5 of 10Figure 5 IL-27 stimulation does not affect TGF-b-mediated activation of Smad proteins in LX2 cells and rat HSC. A, B: LX-2 cells or rat
HSC were pretreated with IL-27 (30 ng/mL) or IFNg (30 ng/mL) for 6 h (A)o r1 2h( B). Expression of Smad2 (A) or phosphorylation and
expression of Smad3 (B) was monitored by Western blot analysis. Staining for tubulin, pY-STAT1 and STAT1 are provided as controls. C, D: LX-2
cells or rat HSC were pretreated with IL-27 (30 ng/mL) or IFNg (30 ng/mL) for 6 h (C)o r1 2h( D) and were subsequently stimulated with TGF-b
(1 ng/mL) for 0.5 h. Expression of Smad2 (C) or phosphorylation and expression of Smad3 (D) was monitored by Western blot analysis. Staining
for tubulin, pY-STAT1 and STAT1 are provided as controls. E: Induction of a Smad2/Smad3/Smad4-dependent CAGA reporter construct after
treatment of LX-2 cells with IL-27 (30 ng/mL), TGF-b (1 ng/mL) or both for 2 h or 16 h. Standard deviations for a triplicate experiment are given
as error bars.
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Page 6 of 10for STAT1 or STAT3 responses could solely be due to
different STAT expression levels (and thus a different
distribution of STAT-dimer species), differences in
Janus kinase activation by specific receptor chains or it
could for example depend on the involvement of speci-
f i cr e g u l a t o r yp r o t e i n s .A sw ec o n s i s t e n t l yo b s e r v ea
much lower STAT3 activation by IL-27 in hepatocytes
and hepatic stellate cells compared to IL-6 one can also
speculate that the STAT3 activation after IL-27 stimula-
tion does not reach a necessary threshold for efficient
induction of STAT3-dependend genes such as SOCS3.
Also, the delayed kinetics of STAT3 phosphorylation if
compared to IL-6 may contribute this effect (figure 2A).
It must be noted however that in HSC SOCS3 upregula-
tion was also not apparent at later time points following
IL-27 stimulation (data not shown). Our present data
fits to our previous observation that IL-27 does not reg-
ulate the STAT3-dependent acute-phase proteins g-fibri-
nogen and hepcidin in hepatocytes and hepatoma cells
[7]. The data suggest that the STAT1 response is the
most important feature in IL-27 stimulated liver cells.
The sustained and efficient STAT1 response upon sti-
mulation of cells with IL-27 is mediated via the WSX-1
chain of the receptor complex [24]. WSX-1 contains a
single conserved tyrosine motif (Y609EKHF) which
resembles the STAT1-recruiting motif of the Interferon-
gamma receptor 1 (Y440DKPH)[29]. Interestingly, this
motif clearly differs from the tyrosine motifs of gp130
that are reported to recruit STAT1 (Y905LPQ,
Y915MPQ) [30]. As these motifs (Y905 and Y915) are also
the motifs that bind STAT3 with the highest affinity
[31] it is conceivable that the competition between
STAT1 and STAT3 at these motifs is responsible for
the inefficient STAT1 activation via the gp130 chain
and/or the preferred formation of STAT1/STAT3
homodimers [10].
It was reported that IL-27 can have antiviral activities
in PBMCs, CD4+ T cells and macrophages and that it
can inhibit HIV-1 replication [27,32]. It can induce IFN-
inducible antiviral genes such as myxovirus protein 1,
2′-5′-oligoadenylate synthetase 2 and RNA-dependent
protein kinase in macrophages, suggesting that IL-27
inhibits HIV-replication by eliciting an interferon-like
response [27]. Similarly, IL-27 has antiviral activity in
hepatoma cells and can induce the expression of IRF-1,
guanylate binding protein 2 and MxA proteins that are
involved in the antiviral response [7]. Importantly, it
was recently reported that patients suffering from a
hepatitis B infection have elevated IL-27 serum levels.
Furthermore, IL-27 levels were also enhanced in patients
with liver cirrhosis or hepatocellular carcinoma [8]. Here
we show that IL-27 upregulates the STAT1-dependent
genes STAT1, IRF-1 and MxA in HSC and that it
initiates an IFN-like response in these cells. Our data
indicate that IL-27 has wide-spread activities in the liver
as it induces genes involved in host resistance to patho-
gens in the two most prominent hepatic cell types. IL-
27 may thus be a suitable candidate for studies on com-
bination therapies against hepatitis C, especially in light
of the fact that novel IFN-based products are currently
being developed [33].
The potential importance of our observations for liver
inflammation is further supported by a recent report
which provides evidence that liver dendritic cells pro-
duce high amounts of IL-27 instead of IL-12 upon
endotoxin exposure [34]. In this experimental setting,
the secreted IL-27 would of course affect responding
liver cells such as hepatocytes and HSC.
STAT1 is discussed to be a negative regulator in liver
fibrosis and its activation was reported to inhibit signal-
ling by TGF-b, one of the major players involved in
liver fibrosis [12,13]. This cy t o k i n ei sak e ym e d i a t o ro f
fibrogenesis because of its ability to induce the transi-
tion of HSC to contractile myofibroblasts and to initiate
the production of extracellular matrix proteins [2]. We
thus investigated whether IL-27 stimulation of HSC
would inhibit TGF-b/Smad2/Smad3 signalling. Such an
effect would be of great interest because many antifibro-
tic drugs aim at the inhibition of HSC activation and
proliferation [1]. As reported by others [13], we investi-
gated whether prestimulation with IFNg would reduce
Smad2 and Smad3 expression. Additionally, we also stu-
died the effects of IL-27 prestimulation on LX-2 cells
and rat HSC. However, an inhibitory effect of either pre-
treatment on TGF-b-mediated Smad2 and Smad3
expression was not apparent in our experiments (figure
5A, B, C and 5D). Nevertheless, it must be noted that
the STAT1-dependent effects on TGF-b mediated fibro-
tic responses may be multifaceted and occur at various
levels. For example, Ghosh et al. proposed that IFNg
activated STAT1 inhibits Smad3 activity by competing
for the interaction with the transcriptional coactivators
CBP and p300 [35]. In addition, IFNg has also been
shown to induce the Smad7, a negative regulator of
TGF-b signalling [13]. Further detailed studies will be
necessary to clarify whether IL-27 can counteract the
profibrotic effects of TGF-b.
Conclusion
Taken together, we show for the first time that IL-27
acts on hepatic stellate cells and that it regulates
STAT1-dependent genes in this hepatic cell type.
Together with our observation that IL-27 also acts on
hepatocytes, a general role for this cytokine in the liver
becomes obvious. We show that the liver cells can con-
tribute to antiviral and inflammatory responses via an
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Page 7 of 10IL-27-induced STAT1 activation. Further studies will
have to deal with the complex interplay between the
various IL-27 responsive inflammatory cells (e.g. dendri-
tic cells, T-cells) and the liver cells in order to dissect
the precise role of IL-27 in liver inflammation.
Methods
Cell culture
Human HSC line LX-2 (kind gift of Scott L. Friedman)
was maintained in DMEM/Nut.MixF-12 medium with
Glutamax supplemented with 2% FBS, 100 mg/L strep-
tomycin, and 60 mg/L penicillin. All human and murine
cytokines used in this study were obtained from R&D
Systems. For cross-talk experiments, the cells were
starved for 12 h and then prestimulated with IFNg or
IL-27 for 6 h or 12 h. Subsequently, the cells were sti-
mulated with TGF-b for 30 min.
Isolation and cultivation of rat hepatic stellate cells
Rat hepatic stellate cells were isolated following a proto-
col that is based on enzymatic collagenase and pronase
digestion of the liver followed by centrifugation of the
crude cell suspension through a Nycodenz gradient.
Details about the purification, seeding, culturing and
estimation of purity were described previously [36].
This two-step protocol yields routinely in approximately
3-5 × 10
7 cells per rat. Experiments were performed at
day 5 after isolation. All experiments were approved by
the Landesamt für Natur, Umwelt und Verbrau-
cherschutz NRW (LANUV), Recklinghausen (AZ 8.87-
50.10.45.08.206).
Reporter gene analysis
Reporter gene analysis was performed as previously
described [7]. The pGL3-(CAGA)12-luc construct (kind
gift of P. ten Dijke) contains a repeat of 12 CAGA ele-
ments that mediate Smad-binding [37]. TGF-b1 stimula-
tion experiments in LX-2 and rat HSC cells were done
with a concentration of 1 ng/ml recombinant human
TGF-b1 for indicated time intervals.
Cell lysis, Western blot analysis and antibodies
Cells lysis and Western blot analysis were performed
as described previously [38]. The following antibodies
were used: anti-STAT3, anti-STAT1 (#610190,
#610116, Transduction Laboratories), anti-pYSTAT3,
anti-pYSTAT1, anti-PLCg, anti-phospho-Smad3
(Ser423/425), anti-Smad3, anti-Smad2 (#9131, #9171,
#2822, #9520, #951, #3103, Cell Signalling), anti-IRF-1,
anti-MxA (sc-497, sc-50509, Santa Cruz Biotechnolo-
gies), and anti-tubulin (Sigma). HRP-conjugated sec-
ondary antibodies were purchased from DAKO. Signals
were detected using the ECL system (Amersham Phar-
macia Biotech).
Detergent-free preparation of nuclear extracts and
Electrophoretic Mobility Shift Assay (EMSA)
The preparation of nuclear extracts and the EMSA were
essentially performed as previously described [10]. Pro-
tein concentrations of nuclear extracts were measured
using a NanoDrop spectrophotometer (PEQLAB). The
DNA-bound STAT complexes were visualized using a
Typhoon phosphorimager (Amersham Pharmacia).
Real time PCR analysis
Total mRNA was isolated with the RNeasy Kit (Qiagen)
according to the manufacturer’si n s t r u c t i o n s .T h ep u r i -
fied RNA was reverse transcribed with the Omniscript
RT Kit (Qiagen) using random hexamer primers. Real-
time PCR was carried out on an ABI PRISM 7000
Sequence Detection System (Applied Biosystems) using
the following primers: b-actin: sense 5′-CCC TGA GGC
ACT CTT CCA G-3′,a n t i s e n s e5 ′-TGC CAC AGG
ACT CCA TGC CC-3′;S O C S 3 :s e n s e5 ′-CAC CTG
GAC TCC TAT GAG AAA GTC A-3′,a n t i s e n s e5 ′-
GGG GCA TCG TAC TGG TCC AGG AA-3′.T h e
relative differences between the cytokine-stimulated and
control samples were calculated with the mathematical
Pfaffl model established for relative quantification in
real-time RT-PCR [39].
Flow cytometry
5×1 0
5 to 1 × 10
6 cells were harvested in cold PBS sup-
plemented with 10 mM EDTA and 0.1% sodium azide.
They were then resuspended in 100 μlP B S / a z i d e( P B S ,
5% FBS, 0.1% sodium azide) and incubated with 1 μg/ml
of monoclonal anti-human TCCR/WSX-1 (R&D Sys-
tems) for 30 min at 4°C. Cells were then washed with
cold PBS azide. To visualize the bound antibodies, the
cells were subsequently incubated in darkness with a 1/
100 dilution of a R-phycoerythrin-conjugated anti-
mouse IgG-Fab (Dianova, Hamburg) for 30 min at 4°C.
Cells were again washed with cold PBS-azide and then
10
4 cells per sample were analyzed by flow cytometry
using a FACSCalibur flow cytometer (Beckton Dickin-
son) equipped with a 488 nm argon laser.
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